Eric Schmidt

Stock Analyst at Cantor Fitzgerald

(3.92)
# 656
Out of 5,033 analysts
53
Total ratings
40%
Success rate
17.69%
Average return

Stocks Rated by Eric Schmidt

Verastem
Oct 16, 2025
Assumes: Overweight
Price Target: n/a
Current: $9.22
Upside: -
Arcellx
Oct 9, 2025
Assumes: Neutral
Price Target: $88
Current: $86.95
Upside: +1.21%
Summit Therapeutics
Sep 8, 2025
Reiterates: Overweight
Price Target: n/a
Current: $20.99
Upside: -
Legend Biotech
Aug 27, 2025
Assumes: Overweight
Price Target: $55$66
Current: $31.96
Upside: +106.51%
Scholar Rock Holding
Jul 17, 2025
Initiates: Overweight
Price Target: n/a
Current: $27.94
Upside: -
Avidity Biosciences
Jun 27, 2025
Reiterates: Overweight
Price Target: $96
Current: $47.89
Upside: +100.46%
Prothena Corporation
Jun 20, 2025
Reiterates: Neutral
Price Target: n/a
Current: $9.92
Upside: -
Cidara Therapeutics
Jun 10, 2025
Reiterates: Overweight
Price Target: n/a
Current: $101.52
Upside: -
Immatics
Apr 1, 2025
Reiterates: Overweight
Price Target: n/a
Current: $9.87
Upside: -
Alumis
Mar 20, 2025
Reiterates: Overweight
Price Target: n/a
Current: $4.49
Upside: -
Reiterates: Overweight
Price Target: $13
Current: $18.25
Upside: -28.71%
Reiterates: Overweight
Price Target: n/a
Current: $4.08
Upside: -
Reiterates: Neutral
Price Target: n/a
Current: $69.15
Upside: -
Reiterates: Neutral
Price Target: n/a
Current: $87.57
Upside: -
Reiterates: Overweight
Price Target: n/a
Current: $42.33
Upside: -
Reiterates: Overweight
Price Target: n/a
Current: $9.03
Upside: -
Reiterates: Overweight
Price Target: n/a
Current: $33.56
Upside: -
Reiterates: Overweight
Price Target: $292
Current: $143.00
Upside: +104.20%
Reiterates: Overweight
Price Target: $370
Current: $416.81
Upside: -11.23%
Downgrades: Neutral
Price Target: n/a
Current: $3.77
Upside: -
Initiates: Outperform
Price Target: n/a
Current: $1.48
Upside: -